-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KQel2tnfZBBsEc6X8OnfNWExXm2iaRfS0uOm7+BFmmc3kUmVQR5t9tVQefAKyvtj
 YmAb/XErc4bV0NzSGLxJQg==

<SEC-DOCUMENT>0001299933-10-003092.txt : 20100816
<SEC-HEADER>0001299933-10-003092.hdr.sgml : 20100816
<ACCEPTANCE-DATETIME>20100816160240
ACCESSION NUMBER:		0001299933-10-003092
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100816
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100816
DATE AS OF CHANGE:		20100816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		101019676

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_38741.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Cumberland Pharmaceuticals Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	August 16, 2010
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Cumberland Pharmaceuticals Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	001-33637
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	62-1765329
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	2525 West End Avenue, Suite 950, Nashville, Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	37203
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	(615) 255-0068
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 2.02 Results of Operations and Financial Condition.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On August 16, 2010, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing the operating results for the three and six months ended June 30, 2010.  A copy of the press release is furnished as Exhibit 99.1.<br><br>This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act.  By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
(d) Exhibits<br><br>99.1  Press release dated August 16, 2010.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Cumberland Pharmaceuticals Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	August 16, 2010
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	David L. Lowrance
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: David L. Lowrance
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release dated August 16, 2010.
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt"><img src="e31153-10228152855181165a_1.jpg">
</FONT>

<P align="center" style="font-size: 12pt"><B>CUMBERLAND PHARMACEUTICALS REPORTS</B>



<P align="center" style="font-size: 12pt"><B>SECOND QUARTER 2010 FINANCIAL RESULTS</B>



<P align="center" style="font-size: 12pt"><I>- New Drug Applications for Caldolor submitted in Australia and South Korea<BR>
&#151; Company converts Field Sales Force to Cumberland employees</I>



<P align="left" style="font-size: 12pt"><B>NASHVILLE, Tenn. &#151; (August&nbsp;16, 2010) &#151; Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX)</B>, a specialty
pharmaceutical company focused on the hospital acute care and gastroenterology markets, today
announces financial results for the second quarter ending June&nbsp;30, 2010, and provides revenue
guidance for full year 2010.


<P align="left" style="font-size: 12pt"><B>Net Revenue: </B>For the three months ended June&nbsp;30, 2010, net revenue was $10.7&nbsp;million, up 9% from
$9.8&nbsp;million for the same period in 2009. This increase was primarily attributable to increased
revenue from Acetadote. Net revenue for the six months ended June&nbsp;30, 2010, was $20.9&nbsp;million, up
9% from $19.2&nbsp;million for the corresponding prior year period. This increase was also primarily due
to an increase in Acetadote revenue over the prior year period.


<P align="left" style="font-size: 12pt"><B>Operating Expenses: </B>Total operating expenses for the three months ended June&nbsp;30, 2010, were $9.7
million compared with $9.2&nbsp;million for the same period in 2009. This increase was due to a 33%
increase in sales and marketing expense, from $4.4&nbsp;million in the second quarter 2009 to $5.8
million in the second quarter 2010, and was primarily due to the expansion of the Company&#146;s
hospital sales force for the launch of Caldolor. That increase was offset by a reduction in
research and development expense, from $2.6&nbsp;million in the second quarter 2009 to $1.0&nbsp;million in
the second quarter 2010 due to a milestone expense related to FDA approval of Caldolor in June
2009.


<P align="left" style="font-size: 12pt">Operating expenses for the six-month period ended June&nbsp;30, 2010, were $19.1&nbsp;million compared with
$16.5&nbsp;million for the same period in 2009. This was due to the aforementioned increase in selling
and marketing expense from expansion of the Company&#146;s hospital sales force offset by the decrease
in expense related to research and development.


<P align="left" style="font-size: 12pt"><B>Net Income: </B>Net income for the three months ended June&nbsp;30, 2010, was $0.3&nbsp;million, or $0.01 per
diluted share, compared with $0.3&nbsp;million, or $0.02 per diluted share, for the same period in 2009.
The change in net income was due primarily to an increase in net revenue offset by increased
operating expenses. While net income for the second quarter 2010 was consistent compared with the
prior year period, earnings per share decreased due to an increase in shares outstanding from the
Company&#146;s initial public offering in August&nbsp;2009. Weighted-average diluted shares outstanding at
June&nbsp;30, 2009, was 16.0&nbsp;million, growing to 21.2&nbsp;million at June&nbsp;30, 2010.


<P align="left" style="font-size: 12pt">Net income for the six months ended June&nbsp;30, 2010, was $0.6&nbsp;million, or $0.03 per diluted share,
compared with $1.5&nbsp;million, or $0.09 per diluted share, for the same period in 2009. The decrease
in net income was primarily a result of increased sales and marketing expense from the Company&#146;s
hospital sales force expansion in the third quarter 2009. The decrease in earnings per share was
affected by the decrease in net income as well as the aforementioned increase in shares
outstanding.


<P align="left" style="font-size: 12pt"><B>EBITDA: Earnings Before Interest, Taxes, Depreciation and Amortization </B>(EBITDA)&nbsp;for the three
months ended June&nbsp;30, 2010, was $1.2&nbsp;million compared with $0.8&nbsp;million for the same period in the
prior year. Excluding $0.2&nbsp;million and $1.2&nbsp;million in non-cash stock compensation expense for the
three months ended June&nbsp;30, 2010, and 2009, respectively, adjusted EBITDA was $1.4&nbsp;million and $2.0
million, respectively. For the six months ended June&nbsp;30, 2010, EBITDA was $2.3&nbsp;million compared
with $3.1&nbsp;million for the prior year period. Excluding $0.3&nbsp;million and $1.3&nbsp;million in non-cash
stock compensation expense for the six months ended June&nbsp;30, 2010, and 2009, respectively, adjusted
EBITDA was $2.6&nbsp;million and $4.4&nbsp;million, respectively.


<P align="left" style="font-size: 12pt"><B>Balance Sheet: </B>As of June&nbsp;30, 2010, Cumberland had $71.5&nbsp;million in cash and cash equivalents,
compared with $73.8&nbsp;million as of March&nbsp;31, 2010. Total assets as of June&nbsp;30, 2010, were $96.7
million compared with $98.7&nbsp;million at March&nbsp;31, 2010. The Company had $13.8&nbsp;million in outstanding
debt at the end of the second quarter, compared with $15.3&nbsp;million at March&nbsp;31, 2010. A large
majority of proceeds from the Company&#146;s initial public offering remains available for planned
portfolio expansion as well as continued development of currently marketed products.


<P align="left" style="font-size: 12pt">&#147;We are pleased to have achieved top line revenue growth in the second quarter and are committed to
building our three marketed products while we pursue new portfolio additions,&#148; said A.J. Kazimi,
Chief Executive Officer of Cumberland Pharmaceuticals. &#147;Our business development and product
development teams are evaluating several new product opportunities. We also remain acutely focused
on expanding hospital formulary approval for Caldolor and have taken a fresh look at the market and
our strategy to build that brand for long-term success.&#148;


<P align="left" style="font-size: 12pt">Cumberland is providing full year 2010 revenue guidance, which represents the Company&#146;s best
estimate of likely future results and which may be affected by factors described below in
&#147;Forward-Looking Statements.&#148; The Company expects its net revenue for the twelve-month period ended
December&nbsp;31, 2010, to be between $42 and $43&nbsp;million.


<P align="left" style="font-size: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>Quarter Highlights</B>
</FONT>

<P align="left" style="font-size: 12pt"><B>Product Development</B>


<P align="left" style="font-size: 12pt"><I>Supplemental New Drug Application for Acetadote</I>


<P align="left" style="font-size: 12pt">In March&nbsp;2010, Cumberland submitted a supplemental new drug application (sNDA) to the U.S. Food and
Drug Administration (FDA)&nbsp;for use of Acetadote in patients with non-acetaminophen induced acute
liver failure. The sNDA included data from a clinical trial at the University of Texas Southwestern
Medical Center indicating that acute liver failure patients treated with Acetadote have a
significantly improved chance of survival without transplant, and that patients requiring
transplant can survive a number of days longer without transplant, providing more time for a donor
organ to become available. In May&nbsp;2010, the FDA accepted the sNDA and granted a priority review. In
addition to expanded labeling, the Company has requested additional exclusivity for the product
and, if approved, expects to begin marketing it with the new indication in 2011.


<P align="left" style="font-size: 12pt"><B>International Markets</B>


<P align="left" style="font-size: 12pt"><I>Acetadote Approved for Marketing in Australia</I>


<P align="left" style="font-size: 12pt">Cumberland has granted an exclusive license to Phebra Pty Ltd., an Australian-based specialty
pharmaceutical company, to commercialize Acetadote in Australia. In April&nbsp;2010, the Therapeutics
Goods Administration (TGA), which regulates drugs and medical&nbsp;devices in Australia, approved
Acetadote for marketing. Phebra is preparing for the Australian launch of the product, which it
expects to commence this year. Under the agreement, Phebra is responsible for ongoing regulatory
requirements, marketing, distribution and sales of Acetadote in Australia, New Zealand and the Asia
Pacific while Cumberland maintains responsibility for product formulation, development and
manufacturing. Cumberland receives milestone payments and royalties on future sales in exchange for
the product license.


<P align="left" style="font-size: 12pt"><I>Caldolor Launched for Compassionate Use in Australia</I>


<P align="left" style="font-size: 12pt">In 2009, Cumberland entered into an exclusive agreement with Phebra Pty Ltd. for distribution of
Caldolor in Australia and New Zealand. The Therapeutics Goods Administration operates compassionate
use programs allowing patients with critical clinical needs to access products not yet approved. In
April&nbsp;2010, Phebra made Caldolor available in Australia for compassionate use.


<P align="left" style="font-size: 12pt"><I>Submission of New Drug Application for Caldolor in South Korea</I>


<P align="left" style="font-size: 12pt">In December&nbsp;2009, Cumberland entered into an exclusive agreement with DB Pharm Korea Co. Ltd., a
Korean-based pharmaceutical company, for the commercialization of Caldolor in South Korea. Under
the terms of the agreement DB Pharm Korea is responsible for seeking regulatory approval for
Caldolor in South Korea, and in April&nbsp;2010 submitted a New Drug Application to the Korean Food and
Drug Administration. Following potential approval, DB Pharm Korea will handle ongoing regulatory
reporting, product marketing, distribution and sales in the territory. Cumberland maintains
responsibility for product formulation, development and manufacturing and will provide finished
product for sale. In exchange for the license to the product, Cumberland will receive upfront and
milestone payments as well as royalties on future sales.


<P align="left" style="font-size: 12pt"><I>License Agreement for Caldolor in Canada</I>


<P align="left" style="font-size: 12pt">In April&nbsp;2010, Cumberland entered into an exclusive agreement with Alveda Pharmaceuticals Inc., a
Toronto-based specialty pharmaceutical company, for commercialization of Caldolor in Canada. Under
the agreement, Alveda will seek Canadian regulatory approval for Caldolor and will handle ongoing
regulatory requirements, product marketing, distribution and sales upon potential approval.
Cumberland will maintain responsibility for product formulation, development and manufacturing and
will receive royalties on any sales in addition to upfront and milestone payments.


<P align="left" style="font-size: 12pt"><B>Share Repurchase Program</B>


<P align="left" style="font-size: 12pt">In May&nbsp;2010, Cumberland&#146;s Board of Directors approved a share repurchase program that authorized
the Company to repurchase up to $10&nbsp;million of its outstanding common shares. During the second
quarter, Cumberland repurchased approximately 200,000 shares pursuant to this program at an average
price of $6.86 per share. Purchases may continue to be made from time-to-time on the open market
over a period of several months. The Company continues to believe that its shares are currently
undervalued and that they represent an attractive investment.


<P align="left" style="font-size: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>Recent Developments</B>
</FONT>

<P align="left" style="font-size: 12pt"><I>Submission of New Drug Application for Caldolor in Australia</I>


<P align="left" style="font-size: 12pt">In August&nbsp;2010, Phebra submitted a New Drug Application to the Therapeutics Goods Administration
for regulatory approval of Caldolor in Australia. If approved, Phebra will handle all ongoing
regulatory requirements, product marketing, distribution and sales in the territory. Cumberland
maintains responsibility for product formulation, development and manufacturing, and receives
upfront and milestone payments as well as royalties on future sales in exchange for the product
license.


<P align="left" style="font-size: 12pt"><I>Field Sales Force Conversion</I>


<P align="left" style="font-size: 12pt">In July&nbsp;2010, Cumberland began the process of converting its field sales force, which promotes
Kristalose and Caldolor, from contract representatives with Ventiv Health to Cumberland employees.
The contractual relationship with Ventiv provided Cumberland with a right to convert the sales
force to Cumberland employees at its discretion. In 2007, Cumberland converted its hospital sales
force from its contractual status in the same manner. The Company expects to complete the field
sales force conversion in September&nbsp;2010 and is pleased to welcome these individuals as Cumberland
employees.


<P align="left" style="font-size: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>Supplemental Financial Information</B>
</FONT>

<P align="left" style="font-size: 12pt">The following table presents a reconciliation of Cumberland&#146;s net income to EBITDA and adjusted
EBITDA. The Company defines EBITDA as net income plus interest, income tax, depreciation and
amortization, and presents these measures to assist investors in evaluating Cumberland&#146;s operating
performance and comparing the Company&#146;s results with those of other companies. EBITDA and adjusted
EBITDA should not be considered in isolation from or as a substitute for net income.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>Three Months Ended June 30,</B></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">279,777</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">287,415</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Income tax expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">374,461</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">232,637</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Depreciation &#038; amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">232,344</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">202,282</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Interest (income)&nbsp;expense, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">355,622</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74,064</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><B>EBITDA</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>1,242,204</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>796,398</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Adjustments:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Non-cash stock compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">204,343</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,164,383</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><B>Adjusted EBITDA</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>1,446,547</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>1,960,781</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="center"><B>Six Months Ended June&nbsp;30,</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">593,275</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,493,266</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Income tax expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">586,198</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,063,696</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Depreciation &#038; amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">463,676</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">398,341</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Interest (income)&nbsp;expense, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">640,895</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">154,179</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><B>EBITDA</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>2,284,044</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>3,109,482</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Adjustments:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Non-cash stock compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">340,242</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,321,445</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><B>Adjusted EBITDA</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>2,624,286</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>4,430,927</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>Conference Call and Webcast</B></FONT>
</FONT>

<P align="left" style="font-size: 12pt">A conference call and live Internet webcast will be held on Monday, August&nbsp;16, 2010, at 5:00 p.m.
Eastern Time to discuss the Company&#146;s second quarter 2010 financial results. To participate in the
call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A
rebroadcast of the teleconference will be available for one week and can be accessed by dialing
800-642-1687 (for U.S. callers) or 706-645-9291 (for international callers). The Conference ID for
the rebroadcast is 90510603. The live webcast and rebroadcast can be accessed via Cumberland&#146;s
website at <U>http://investor.shareholder.com/cpix/events.cfm</U>.


<P align="left" style="font-size: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>About Cumberland Pharmaceuticals</B>
</FONT>

<P align="left" style="font-size: 12pt">Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on
the acquisition, development and commercialization of branded prescription products. The Company&#146;s
primary target markets include hospital acute care and gastroenterology. Cumberland&#146;s product
portfolio includes Acetadote<sup>&#174;</sup> (<I>acetylcysteine</I>) Injection for the treatment of
acetaminophen poisoning, Caldolor<sup>&#174;</sup> (<I>ibuprofen</I>) Injection, the first injectable treatment
for pain and fever available in the United States, and Kristalose<sup>&#174;</sup> (<I>lactulose</I>) for Oral
Solution, a prescription laxative. Cumberland is dedicated to providing innovative products which
improve quality of care for patients. For more information on Cumberland Pharmaceuticals, please
visit the Company&#146;s website at <U>www.cumberlandpharma.com</U>.


<P align="left" style="font-size: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>About Caldolor</B>
</FONT>

<P align="left" style="font-size: 12pt">Caldolor is indicated for the management of mild to moderate pain and management of moderate to
severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It is
the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with
known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic
type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the
peri-operative period in the setting of coronary artery bypass graft (CABG)&nbsp;surgery. Caldolor
should be used with caution in patients with prior history of ulcer disease or GI bleeding, in
patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart
failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be
monitored during treatment with Caldolor. For full prescribing information, including boxed
warning, visit <U>www.caldolor.com</U>.


<P align="left" style="font-size: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>About Acetadote</B>
</FONT>

<P align="left" style="font-size: 12pt">Acetadote is used in the emergency department to prevent or lessen potential liver damage resulting
from an overdose of acetaminophen, a common ingredient in many over-the-counter painkillers. It is
the only approved injectable product in the United States for the treatment of acetaminophen
overdose, the leading cause of poisonings presenting in emergency departments in the
country<sup>1</sup>. Acetadote is contraindicated in patients with hypersensitivity or previous
anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious
anaphylactoid reactions, including death in a patient with asthma, have been reported in patients
administered acetylcysteine intravenously. Acetadote should be used with caution in patients with
asthma, or where there is a history of bronchospasm. The total volume administered should be
adjusted for patients less than 40 kg and for those requiring fluid restriction. To avoid fluid
overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid
overload can occur, potentially resulting in hyponatremia, seizure, and death. For full prescribing
information, visit <U>www.acetadote.net</U>.



<P align="left" style="margin-left:4%; font-size: 12pt"><sup>1</sup> <sup>National Poison Data System, American Association of Poison Control
Centers</sup>


<P align="left" style="font-size: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>About Kristalose</B>
</FONT>

<P align="left" style="font-size: 12pt">Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique,
proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient
age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.
Excessive dosage can lead to diarrhea with potential complications such as loss of fluids,
hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in
diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly,
debilitated patients who receive lactulose for more than six months should have serum electrolytes
(potassium, chloride, carbon dioxide) measured periodically. For full prescribing information,
visit <U>www.kristalose.com</U>.


<P align="left" style="font-size: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>Forward-Looking Statements</B>
</FONT>

<P align="left" style="font-size: 12pt">This press release contains forward-looking statements, which are subject to certain risks and
reflect Cumberland&#146;s current views on future events based on what it believes are reasonable
assumptions. No assurance can be given that these events will occur. As with any business, all
phases of Cumberland&#146;s operations are subject to factors outside its control, and any one or
combination of these factors could materially affect Cumberland&#146;s results of operations. These
factors include market conditions, competition, an inability of manufacturers to produce
Cumberland&#146;s products on a timely basis or a failure of manufacturers to comply with regulations
applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing
infrastructure and other factors set forth under the headings &#147;Risk factors&#148; and &#147;Management&#146;s
discussion and analysis of financial condition and results of operations&#148; in Cumberland&#146;s Form 10-K
filed with the SEC on March&nbsp;19, 2010. There can be no assurance that results anticipated by the
Company will be realized or that they will have the expected effects. Readers are cautioned not to
place undue reliance on forward-looking statements, which speak only as of the date hereof. The
Company does not undertake any obligation to publicly revise these statements to reflect events
after the date hereof.


<P align="left" style="font-size: 12pt">SOURCE: Cumberland Pharmaceuticals Inc.

<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="37%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Investor Contact:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Media Contact:</B></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Angela Novak<BR>
Corporate Relations<BR>
(615)&nbsp;255-0068<BR>
anovak@cumberlandpharma.com
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rebecca Kirkham<BR>
Lovell Communications<BR>
(615)&nbsp;297-7766<BR>
rebecca@lovell.com</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 12pt">MORE



<P align="center" style="font-size: 12pt"><FONT style="font-size: 10pt"><B>CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES<BR>
Condensed Consolidated Balance Sheets<BR>
(Unaudited)</B></FONT>


<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="68%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>December 31,</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 8pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt"><B>ASSETS</B></FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Current assets:</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px"><FONT style="font-size: 10pt">Cash and cash equivalents</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt">$</FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">71,495,305</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt">$</FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">78,701,682</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px"><FONT style="font-size: 10pt">Accounts receivable, net of allowances</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">3,960,129</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">6,176,585</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px"><FONT style="font-size: 10pt">Inventories</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">7,967,089</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">4,822,873</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px"><FONT style="font-size: 10pt">Other current assets</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">3,238,151</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">3,472,455</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px"><FONT style="font-size: 10pt">Total current assets</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">86,660,674</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">93,173,595</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Property and equipment, net</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">958,766</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">918,412</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Intangible assets, net</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">7,705,084</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">7,956,009</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Other assets</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">1,377,506</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">1,676,304</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 1pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">Total assets</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt">$</FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">96,702,030</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt">$</FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">103,724,320</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 1pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt"><B>LIABILITIES AND EQUITY</B></FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Current liabilities:</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px"><FONT style="font-size: 10pt">Current portion of long-term debt</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt">$</FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">6,000,000</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt">$</FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">9,061,973</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px"><FONT style="font-size: 10pt">Current portion of other long-term obligations</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">24,592</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">144,828</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px"><FONT style="font-size: 10pt">Accounts payable</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">5,993,006</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">5,632,796</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px"><FONT style="font-size: 10pt">Other accrued liabilities</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">3,409,097</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">3,784,777</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px"><FONT style="font-size: 10pt">Total current liabilities</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">15,426,695</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">18,624,374</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Revolving line of credit</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">1,825,951</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">1,825,951</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Long-term debt, excluding current portion</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">5,938,027</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">8,938,027</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Other long-term obligations, excluding current portion</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">209,327</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">184,632</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px"><FONT style="font-size: 10pt">Total liabilities</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">23,400,000</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">29,572,984</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Commitments and contingencies</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Redeemable common stock</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">&#151;</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">1,930,000</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">Equity:</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px"><FONT style="font-size: 10pt">Shareholders&#146; equity:</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">Common stock &#151; no par value; 100,000,000
shares authorized; 20,358,586 and
20,180,486(1) shares issued and outstanding
as of June&nbsp;30, 2010 and December&nbsp;31, 2009,
respectively</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">68,199,165</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">67,711,746</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">Retained earnings</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">5,153,008</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">4,542,126</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">Total shareholders&#146; equity</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">73,352,173</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">72,253,872</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px"><FONT style="font-size: 10pt">Noncontrolling interests</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">(50,143</FONT></TD>
    <TD nowrap><FONT style="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">(32,536</FONT></TD>
    <TD nowrap><FONT style="font-size: 10pt">)</FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">Total equity</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">73,302,030</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt"></FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">72,221,336</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 1pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">Total liabilities and equity</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt">$</FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">96,702,030</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="font-size: 10pt">$</FONT></TD>
    <TD align="right"><FONT style="font-size: 10pt">103,724,320</FONT></TD>
    <TD><FONT style="font-size: 10pt"></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD><DIV style="margin-left:50px; text-indent:-10px"><FONT style="font-size: 10pt">&nbsp;</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><FONT style="font-size: 11pt"> </FONT><FONT style="font-size: 8pt">(1)&nbsp;Number of shares issued and outstanding represent total shares of common stock
regardless of classification on the consolidated balance sheet. The number of shares of
redeemable common stock at December&nbsp;31, 2009 was 142,016.</FONT></TD>
</TR>

</TABLE>


<P align="center" style="font-size: 8pt"><FONT style="font-size: 10pt"><B>CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES<BR>
Condensed Consolidated Statements of Income<BR>
(Unaudited)</B></FONT>


<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>Three months ended June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>Six months ended June 30,</B></TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">10,739,935</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">9,820,613</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">20,870,587</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">19,225,212</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Costs and expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Cost of products sold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">863,725</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">777,076</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,723,013</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,510,294</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Selling and marketing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,848,123</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,383,802</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,455,635</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,523,989</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,034,800</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,630,725</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,808,668</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,400,842</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,782,834</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,236,435</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,664,037</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,681,298</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Amortization of product license right</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">171,726</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">171,726</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">343,452</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">343,452</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28,867</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26,733</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55,414</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54,196</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Total costs and expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,730,075</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,226,497</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19,050,219</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,514,071</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Operating income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,009,860</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">594,116</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,820,368</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,711,141</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50,334</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,160</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">111,013</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,756</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(405,956</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(84,224</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(751,908</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(181,935</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net income before income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">654,238</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">520,052</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,179,473</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,556,962</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Income tax expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(374,461</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(232,637</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(586,198</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(1,063,696</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">279,777</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">287,415</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">593,275</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,493,266</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net loss at subsidiary attributable to</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">noncontrolling interests</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,527</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,456</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,607</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,695</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net income attributable to</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">common shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">287,304</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">295,871</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">610,882</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,513,961</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD colspan="5" align="left">Earnings per share attributable to common shareholders<BR></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">- basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">- diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.09</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Weighted-average shares outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">- basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,445,560</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,467,781</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,340,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,394,883</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">- diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,207,645</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,046,844</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,302,119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,087,448</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 9pt"><FONT style="font-size: 10pt"><B>CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES<BR>
Condensed Consolidated Statements of Cash Flows<BR>
(Unaudited)</B></FONT>


<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="74%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>Six Months Ended June 30,</B></TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Cash flows from operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">593,275</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,493,266</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Adjustments to reconcile net income to net cash flows from operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Depreciation and amortization expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">463,676</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">398,341</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Non-employee equity compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,554</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,008,381</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Stock-based compensation &#151; employee stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">318,139</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">313,064</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Excess tax benefit derived from exercise of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(462,814</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(2,842,825</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Non-cash interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">132,866</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,376</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Net changes in assets and liabilities affecting operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px">Accounts receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,216,456</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(125,024</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px">Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(3,144,216</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">654,400</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px">Other current assets and other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">349,777</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">743,951</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px">Accounts payable and other accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">337,995</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(986,592</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:40px; text-indent:-10px">Other long-term obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(95,541</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">582,254</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Net cash provided by operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">755,167</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,268,592</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Cash flows from investing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Additions to property and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(126,315</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(85,863</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Additions to patents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(80,734</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(34,551</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Net cash used in investment activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(207,049</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(120,414</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Cash flows from financing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Costs of initial public offering</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(154,179</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Principal payments on note payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(6,061,973</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(416,667</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Costs of financing for long-term debt and credit facility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(55,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(15,475</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Proceeds from exercise of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">979,292</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,296</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Excess tax benefit derived from exercise of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">462,814</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,842,825</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Payments made in connection with repurchase of common shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(3,079,628</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(2,707,419</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Net cash used in financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(7,754,495</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(446,619</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Net (decrease)&nbsp;increase in cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(7,206,377</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">701,559</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Cash and cash equivalents at beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">78,701,682</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,829,551</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Cash and cash equivalents at end of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">71,495,305</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">12,531,110</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Supplemental disclosure of cash flow information:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Cash paid during the year for:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">503,250</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">116,848</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50,650</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">93,969</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Non-cash investing and financing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Increase in accounts payable and accrued expenses of initial public offering</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">119,646</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 9pt">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Common shares repurchased during period but not paid as of the end of the period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">203,802</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 9pt"><FONT style="font-size: 11pt"># # #</FONT>




<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e31153-10228152855181165a_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e31153-10228152855181165a_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!=`9P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^^BBBB@`H
MHKQGQI\?OA5X$G>SUOQ5:S:A;W_]EZCINBVNJ>(M0T2^?P^WB>UA\26WA_3]
M4/A5-0T7R;K3[[Q4VB:9>M?Z5;V]])=:OID-W=.G4JRY*4)U)?RPBY/=+9)]
M6@NENTO5I?F>S5QE[\0/"FG^/O#GPPNM7MX?'/BSPGXS\=:!X?=+G[5J/A/X
M?:KX%T/Q?K4,BV[6@M]%UCXE^!K"XCEN8IY)?$$#6T4Z6]VT'XR?M(?\%I]`
M^%^C6[_#;X$^*==UN:#6HM03XC^)=`\)VVAW444T.BWD5IX0;XAKXGMI;U8[
MJ\T[^VO"LO\`9SHJZE%>O)!:_F5_P1S_`&P/CI^V?_P5]^*OQ'^.7B.SU34-
M)_8D^)6@^%?#FA:?_8W@_P`%>'F^//P&U+^Q/#.D-<7MTEL;R\FDFU'6M3UK
MQ%J"):Q:KK>H)8V0@^PP?!&;U,MS/.,;3AA,!E^`Q&*BY5:<Z^)JQCRTJ<*5
M-S<(*I*,ZDZDH>Y%QA&3FG'Q\;G%'"U\%AH)U*N+QM#"[-0IQG/WY.3WDHJ7
M*DFKV;=M_P"P.BD'0?0?RI:^,/8"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`KA/B7\3/`_P?\$Z]\1/B-XCT[PKX0\-VBW>
MJZQJ<DJPH9KF"QL;&TM[:&YO=3UG6-2N[/1_#^A:7:WFL^(==O\`3M"T6QO]
M6U&RLY^[K^5C]OC]I/X@_MF_M=7G[,OP8\*:YXO\&?`+Q?J&B)IOA32/&&KZ
MGXE^)NFRVO@KQYXO\0Z7<Z'IT.A:%\/-<U'4/A_I>O-8W/AZPTR3Q)XX/CFZ
M\)>.K6+1O>X>R.IGF-E1=58;!X6D\5C\7)QC"AAH2C%I3G:FJU64E3HJ;MS-
MS<7"G.W+BL2L/"+LY5*DE"G!)MRENW9)OEC%.4O1)-.2:_1&^_;/\6?M`>)[
M.V\&MK7@#X9P_P!DSVNG)/\`V7XZUG5-.UJ+6FO/$6OZ#JLZ66D2'3M'L3X1
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MME]W7K<_CL_:\^]>_6;_`-"K<_X-Q?\`E)U\7O\`LSCXD?\`JZ_V?*_JG\8?
M\$P?V(/B`_F^,/@U=ZO,3F1XOBI\9M'65L`%I+?0OB'IELS.!^\`A".6?Y`K
ME:_/C]LS]C+]G']@CX<:/\<?V/O`-]\!OBYXD\;:7\--<^('@WX@?$IO$FJ>
M`]6T'Q)XHU/PO=WFM>+]5#Z7?^(?!OA;5;J,)YD]UHEBTDC+&4;['$>(.3U.
M&\SR:&%S-XG&X&IAJ=25'"QHPJ2Y+.<EC)3Y/=WC!O5Z::^'BLDQ-?&X#$QJ
MT8PPF.I8JI%N?-*$'[T86A9RLW:[2;5FU>Z_H`'0?0?RI:_CRLO^"D?[:WA*
MSALM,^.>KWEK!*CLOB/PUX'\5W-PB2LS0W&J>)/#&IZNZ2@LLCKJ"3\AXYDD
M1'7ZT^%O_!=;QWHNJ6]E\>/@_P"'/$FA2WVGV\^O?"Z\OO#.N:5IB1R+J=_+
MX=\37OB'3?%.J2/Y,UK9V^O^![$-YL3S+'(C0?D!],?TLT5\Q?LX_MA?`']J
MC18=1^$GC>UO]973EU+5_`NL1OHOCKP_"L>F->-J7AV\VSW=CIMUJ]CI=WXC
MT&76O",FK2MIVG^(;ZXCD5?IV@`HHKX$_P""G/[:%U^P!^Q?\6_VGM*\(:?X
M]\1^"T\*:3X3\):MJ]SH>F:OXD\:>-/#O@VPDU"_M-.U*X-CH46NW7B>^T^&
M.SGUFQT.ZT6VU?1;K4(-6L^K!8/$YCC,+@,'3]KBL;B*.%P].ZCSUJ]2-.G'
MFDU&*<I*\IN,(K6<HQ3DN?%8JC@L-B,9B9JGA\+1JXBM-IODI48.I.5HIRDU
M&+M&*<I/2*;:1]]T5_('\,O^"G__``<@?&/X>^#?BI\-/^"=G[,'B[X?_$#P
M[I?BSP=XFM/#GBVUM=<\/:U:QWNF:G;V^H_M>65_##=VTL<L:7EI;W"J0)8D
M;(KH?$7_``42_P"#F'POH&M^)M>_X)L_LR:5H?A[2M0US6=3ET#Q))'I^DZ5
M:37^HWLD<7[84TKI;6EO+*ZQ122E5/EQR/A3]I+P\S6-:5"6;<*QK1JNC*D^
M),L52-6,U3E3=-UN=3C.\7#EYN96M=I'S:XQP$H1JPRWB*=*4%4C5CD&9NG*
MG*,9*I&:P_*X.+YE).S6M[-'];=%?DG_`,$9O^"COB7_`(*:?LH:M\9_'G@3
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M"A2O2DHRB_:5(QFI6<-;['[ZT4#D`^M?GA_P58_:S^(W[#?[!OQT_:C^$VC>
M"O$/C_X8#X9'0=&^(FFZYJW@Z]_X33XS?#GX=:J-8L/#?B+PGK<_V?1?%^I7
M>G_8?$&G^7JD%E-=?:[..>RN?'P.#KYCC<'E^%498G'8K#X+#QG)0C*OBJT*
M%&,IO2$74J13D](IMO1'IXO$TL%A<3C,0W&AA*%;$UI).3C2H4Y5:CC%:RDH
M1;45K)V74_0^BOSQ_P""4W[6/Q'_`&X_V"/@/^U)\6M'\%Z!\0?B@/B>-?TC
MX>:;KFD>#[3_`(0KXR_$3X>:6=(T[Q'XC\6:Q;FXT7PGIMUJ'VO7[\2ZI/?3
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M*#J?&WC/PS\.O!_BKQ_XUUO3?#/@WP1X=UKQ;XM\2:U=I8:/X?\`#7AS3KC5
M]=UO5;V0&.TT[2M+M+J_OKF3Y(+6WED;A37A2HUH5GAY4JD:\:CHRH2A)5HU
M5+D=)TVE-5%/W'!QYE+W;7T/8C4ISIJM&I"5&5-58U5*+INDX\ZJ*=^5P</>
M4KV<=;V.HHK^67_@F5_P7H^-'_!0W_@HWXG_`&>+3X9?##P=^S/<>'_BMXJ^
M'5_+H/BJ+XWRZ#X1ELD\)R^,]87XCZQX$BU35+.X^WZ_I>A^%3:Z9<7`TFPU
MK4DL#K&I?T'_`+7_`,6?$GP#_9/_`&F_CKX.L]%U'Q;\%_V?OC'\5_#&G>)+
M:]O?#NH>(?AW\//$/B[1K'7K33=0TC4;G1KO4-'M[;5(-/U73+^6QEN$L]1L
M;DQW,?MYKPSF^39IA,FS"C3I9AC:6"JTJ*K0FHK'3=.C&I./NPFIIQJ1;M%K
M>VIY67Y[EV9X#$YE@ZDZF$PT\3"=1TY1<OJJ;G*G&23E"25Z<M.96;Y;GT71
M7\8G[,W_``61_P""_O[8WP^O_BG^S5^PK^R5\4_`.E^*=1\$W_B+2]"\7Z/;
MVWBC2M,T;6+_`$EK7Q3^UUH>HO+;Z;X@TBZ:>.S>T=;U$BN))8YXXOH"Z_;K
M_P"#GRSMKB[G_P""97[,!BMH9)Y%@T_5+RX9(U+LL%I9_MFSW5U,P&V*VMH9
M;B>0K%#%)(RH??K>'>;X:M/#XC-.%\/B*4^2K0K\19;2K4Y^[>%2E4JQJ0FK
MZQE%25M4>32XSR[$4X5J&7\05J-6*G3K4LAS*I2J0E:TX5(4)0G%IW4HR<6M
MGJC^KNBOP+_X(@?\%<_BG_P4LL_C]X*^/GPM\%_#7XO_``&O?!D]]+X"C\4Z
M/X?\0Z-XRG\8V$MF?!_BV^\3:WX8UGP=J7A!;366O_&>J'5Y=?M_LNF:.=)O
M([CV#_@N!_P4+^-/_!-;]E7X=_'3X%^&OAAXJ\5^*_V@_#'PGU+3/BQHOBK7
M?#L7A[7?AQ\5?&%S?65KX0\:>!=3BUN'4_`FDP6UQ/J]S8+8W6I12Z;-<2VM
MU9^)/A7.:7$<>%:U&G3S>=>C0C3E6@Z$I8BC&O1G'$1YJ<J=2E.,XR3TORS4
M9*27I1XARR>1RX@A4J3RZ-&I6E-4JBJI4JLJ%6#HSC":G"M&5-II*\>9-Q:D
M_P!E**_D/\`_\%+_`/@Y+^*'@7P7\2_`7_!.+]F'Q)X&^(?A/P[XY\&>(K7P
M]XJ@M=?\*>+-(M->\.ZU;0WW[7]K>Q6^J:/?V=]`EW:V]RL5PJSP12!D'6_\
M-Z_\'.__`$C)_9H_\$?B#_Z,:O8EX?YE"4H3SGA.,X2<)QEQ-E2E&<6HRC).
MO=2C*Z:>J:L]6<$>+\%)1E'*^))1DHRC*/#^:-.,E%IIK#V::E=-:-6:W1_6
M'17SW^REXN^./CS]G7X0^,/VE?!6C?#GX\^(?!MAJ7Q2\#>'H)K71/"_BR62
M=;_2=+@N/$/BR=+2W5(C%YGB36BRN'%_,&!'\MFI_P#!;'_@L%\4OVW/VL_V
M1_V-_P!E;]EGXTS_`+.GQ8^-GARSM-2\-^.['Q0WPY^&'Q;O?AIIWB3Q#J6K
M_M+>"?#U[JMQ))H2:H-%L;&.:_OY)[+1K2Q5H[;R,GX6S'.Z^9T<'6RZ$<I3
MEC<5BL?0PV"A#V[PZJ1Q55QHRI2J+W*G,H2BXR3M)'=F'$."RRGE\\12QTIY
MGIA,/0P5>OBI25&->4)8:G%UHSA3;<X.'-%QDI)69_8O17\I9_;C_P"#H`<G
M_@F9^RT!QR8+SN<#_F]+UKUG_@C_`/\`!9C]J;]LO]KGXT?L9?MB?`GX;_";
MXG_#3P9XM\51S_#_`$WQMX1N-#UKX?\`B[PMX.\4^`/%OA#QCXE^(-Q<:I+<
M>*7U6S\06?B?1;&Q@T&YT]M(U=]9L]0LO0Q7`F<8?`8W,*6+R/,:.7THXC&0
MRS.\!CJ]##N48.M.C0JRFH1E))Z7>O*G9HY:'%N6U<5A<'5P^;8*KCJKHX5X
M_*<=@Z5:LH.?LH5:]&$7/E3=E?;6R:/Z6Z*_/'_@JM^UE\1OV'/V"_CK^U)\
M)M&\%^(/'_PO7X8G0=&^(>FZYJW@Z]_X3;XS?#GX=:I_;%AX;\1^$M;G^S:)
MXOU*ZT_[#XAT_P`O5(;*:Y^UVD<]C<K_`,$I_P!K'XC?MQ_L$_`?]J7XM:-X
M*\/_`!`^*'_"T!K^D?#S3M<TGP?:?\(3\9_B+\.]+.D:=XD\1^+-9M_M&B^$
MM-NK_P"UZ_?^;JD]]/;?9+26"QMOG_['QW]B_P!O\E/^S?[4>3>T]I'VOUY8
M18YP]C\7LUAY)^U;2YGRI-WMZ_\`:>$_M5Y,I3^O+`?VFX<C]FL)]8^JJ?M/
MAYW7]WV:N^7WGH?H;1117EGH!161K^O:+X6T35_$OB35=.T'P[X?TR_UK7M=
MUB]M]-TC1='TNUEO=3U75=1O)(;/3]-TZR@GO+Z_O)H;2SM89;FYFB@BDD7^
M/KX,_P#!S#\3O&?[:/@C2_B)\+?AAX)_X)V?%+X__$#X*>!OC7?:%XG\/?$"
MVM-$L]`BT3Q3XR\9^*/B98_#?2+?PU-\1?A1XR^,-F?"ML?`7@'QBTXO-5N[
M"TO-;]_)>&<XX@I9C6RO#*O#+,.\1B.:K"E*?N3J1H8>,VGB,34A2JRIT:=Y
MR5.5M58\?-,]RS)ZF"I8^O[*>/KJA12C*=KRIPE5JN*:I4(3JT83JS:BI58)
MO5M?V.445X/^U+\3-?\`@M^S/^T+\8_"=KI%[XI^$_P0^*_Q*\-V?B"VN[S0
MKO7O`W@/7O$^D6NM6FGW^E7]SI-Q?Z7;PZE;V.J:;>36;S1VM_9SM'<1^)2I
MSK5:=&"O.K4A3@F[)SG)1BFWHKMK5['JU)QI4YU)7Y81E.5M7:*N[+O9'O%%
M?RR?\$A/^#BW3?VROBG+^SI^V5H?PV^#/QC\;:W;6GP+\7>`K?7]!^%'CV]N
MX;.VM_A;JD'C'Q7XRU7PU\3M3U`S3^#+N[\22^'OB%+=Q^#-.M]!\;6_AC3/
MB1_4W7JY[P_FO#>/GEV;X9X?$1C&I!J2J4*]*6U7#UH^Y6IWO%R@WRSC*$K3
MBTO/RC.,OSS!PQV75U6HR;C)-.-6E4C\5.M2E:=*:TDHR2YH.,XWA*+917\\
M?_!0O_@K!^T;^RC_`,%5OV)_V'/ASX0^"^K_``F_:4;]FY/&_B'QGX;\;:E\
M1-&'Q>_:,\7_``D\4MX2U?1?B)X>\-63VOAG0[2\T,ZUX2U]+/6WGNKY-3L7
M338_Z'*RQ^48W+<-E>+Q481I9OA)8W!N%13E*C&K.BW-+X)<\'[KUMKLR\'F
M>%QV(S##8>4G5RS$QPN*4H2BHUI4H5DH-JTX^SG'WH];KI=E%?R<?MH?\%F/
M^"FGP]_X*=_%K_@GW^QC^SU^SA\:;[PM;^"KWP)I7C#POX]G\?:W:ZO\!_!?
MQB\5/J>L6OQW^'WA.8:,==UPVIM]+TIO['L;6"1+W4%DN+JMJ7_!0/\`X.<M
M-L+O4)_^"9/[.IM[*"2YG73O"GB[5KYHH1O=;73-,_:[OM1OYBH(2VL;.YN9
M6(2&)W*BOIH>'^<.A@J]?'\/8+^T,'A,?AJ..SW`83$2PN-IPJ8>HZ%>I"HE
M.,[7LXJ<9PYFXNWB/C'+/:XFG3PF=8E83%8C!UZV$R;'XG#QQ&%G[.O35:C1
MG3DX3WL[V<962DC^M"BOY,OV9O\`@Y!^)?@SXR>$?V?O^"JO[).M?LD>)_%Z
M6]S;?$V'P[\0/AQH>CVNO:O#HOA;5/%?P@^+UI<>+-%\`3W5GXE_M;XGZ?\`
M$'Q#;65QI]M%_P`(F=+36M>TC^D/]H7XV:S\)],^&FE>!O".G^/_`(F?&OXF
M:=\*?A=X8UGQ+-X+\-W^O_\`",^*_B/XJU/Q%XMB\.^*GT32?"/PE^'7Q)\=
MNL6@W][XAG\*V_A+1HCK?B'3"/%S7AC.LEQ.&PN/PL(O&TY5\'B*.(P^(P6*
MH4[NI7HXVC4GAW2HQ7/7<YPEAZ=IUXTXM,]/+L^RO-</7Q&#Q$I_59QI8JA4
MHUJ.+PU:7PT:V%K0A7C4F[QIKD:K235)S>A]%45^6'[!7[?/BW]J;7KKP[XC
M\&0WNB:A:?$#4/!OQ>\,Z;X,\/>$M>F^&"?!NX\9Z"^A^!_CW^T]X3NH;./X
M]^!=+T#Q?X3^.GBR76/&_A3X\>`O'W@/X,^(OA%IMO\`$C]3Z\O'8#$Y=B)8
M;%04*L5?W9*<91YI133B]'>,E*,K3A).,XIH]#"XJCC*4:U%MPE;XHRBUS1C
M-)II:N,HRNKQ::<9---\1\3+OQS8?#KQU??#'1-&\2_$BQ\(>([WX?\`AWQ%
MJ;:)X?USQM::3=W'A72-<UA(+I])T?4==CL;34M3CMKB6PLY9KJ."9XEC;PC
M]CW]CSX1?L7_``DT/X9_#'0],&JIH^BVWCWX@+I,-CXF^)6OZ5%=M)K_`(BN
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MJD&FP^#/']G-J,VGZ+9WMW'8PW=_96TUV\(MXI[RVB>17GB5OTUHH`_B"\0_
MLP_M+6UK)=7'[._QU@M45Y'N9OA%\0(H$C3<[NTS^'EC5%4$LQ8*`&R?E./C
M7Q39W>GWMUI]_:W-C?VDKQW=C>02VUY:2*(]T=U;3*D]O(/.BS',B.-Z_+S7
M^B/56]L;/4K2YT_4;6WOK&\ADMKNSNX8[BUNK>52LD-Q;RJ\4T4BDJT<BLK#
MJ*`/X2/V?]2U/1M1T75M%U/4M%U;3IX;O3M6T?4+S2M4T^[B;=%=6&HZ?/;W
MEE=1'F*YMIXIHF^:-U/-?UC_`+'/[5^H_&"QM/!?Q!CMD\<V^G>;8:[8VT%E
M9^*ELH&DO!<:=;[(;+7Q;0RZG<1Z=;PZ1=PI?2V=II*6L=E+W_B_]@[]DKQ?
M!`H^!_@?P=>V<&H1:?J?PVTF'X<W-I/J**LE_-;>#1HVDZW>6LBBXL?^$FTW
M6[2VN#(WV22*YO(;CYB\1?L0ZY\(OMOB+X<ZYJ_C?PMI$8U6/1Y!<V?Q0TK^
MS!X?:WET.Y\+VUG%XIU>&[7Q'XCBN]`A\'^(M.73]!T7PMH7B7Q%,NH.`?JQ
M7\]O_!SG_P`HK?&?_98O@]_ZD%Q7[H_"OQ?<>._A_P"&?%-ZD2WVI6!^W/;V
M]O:6-W>6L\MG/J>EVEOK?B+[+HNL-!_:^A6]UK-YJ<6BWVGKJPMM3^UVL'XC
M_P#!R_H.HZQ_P2A^*VH64:O:^%?B/\&-?UAV+#R=/N/B%H_A:%TPC*7;5O$N
MEQ;7>,;)'8,S*$;ZO@62CQEPPY-)?VWET;MVUEB81BO64FDEU;21\[Q;&4N&
M,_44V_[)QKLM[*A-OY))M^5S[O\`^"37_*,W]A3_`+-?^#__`*AVF5]V^*/#
M6B^,_#>O^$/$EF=1\.^*=%U7P[KVG"YN[+[?HVMV,^FZG9?:]/GM;^V^U6=S
M-"9[.ZM[F(/YD$T4JHZ_S3?\$]?^"Z/_``2T^!?[#?[)_P`'?BC^TY-X9^(W
MPT^`_P`-_!GC;P]_PI/]H36O[%\2Z#X:L+'5M,.K>'?A3J^A:B;2ZBDA-YI&
MJ:AITY0O:7EQ"5E;Z.^)W_!Q'_P2HD^&_P`0%^'?[7$A^(!\%>*3X%#?`']H
MI1_PF2Z'?MX7(;6_@N=&5AKBV.QM7']EJ^TZ@RVGFL/2SGA'BNOQ!F=7#\.Y
M]R5<WQCHXB.4YA[-*6,FH5E5CA](1;4_:Q=HQ7M(MI)G-E_$G#E/*L#&IGF3
M<U/+<*JE&69X'GYH86GSTW3E73YTURN$DGS>ZU<_3O\`9)_8C_9B_87\%^)/
MAY^RS\,A\+?!WBWQ.?&7B#1QXS^(7C8:AXE;2M/T1M3.H?$7Q7XNU2U)TO2M
M/M?LEE>VU@!;B7[+Y\DLLG\RG_!;/_E.S_P1P_[*%^R]_P"M?VU?H[_P;O\`
M[8_[4O[</[)WQB^+G[5/Q,7XH^*-!_:)U?X=>&M8'A'P!X+?3]"T;X9_#/Q+
M-IATGX>>%/"6E3QK?^,);J/4+NQN+Z9[F:V>Z\FTABC_`#._X.!M;TGX*_\`
M!6;_`()+?M(_$J\;P[\'?!WB[X7ZUXE\5KI^JZM_9FE_!G]I#PKX\^(MV-*T
M6PU#5M2_L#PKXIT75&L=&LM1U>]6Y^S6&FW-X]K;W7O\,8#,,N\0\SRO,\:L
MSS6&69]AJN)IXC$XV>,Q,LEK34:=7$PABJ]11:A:=-3O!I*R1X7$&+P.+X(P
MN-P&'6!R^KB,HK4:$J='#PP]%YKA?BA1E*A1@G>3<9^S2?,W;4_LK'0?0?RK
M\4?^#B3_`)0]_M=_[GP$_P#6I/@=2#_@XF_X(\#C_AKF;CC_`)-__:>_^<Q7
MY??\%F?^"S?_``3:_:Q_X)N_M&?`+X`_M%OX[^+7CP?"(>%/"C_!_P"._A8:
MK_PC'QZ^%GC773_;OC+X8>'_``W8BP\->&M8U$C4=8LS=?919V0N;^XMK6;P
M^%^%.*,-Q-PYB,1PYGM##T,^R:M7K5<IQ].E1HTLQPM2I5J3EAU&%.G!.<YR
M:C&*;;23/5X@XAR"OD.=4:.>9/6K5LIS"G2I4LSP4ZE6I4PE6,*=.$:[E.<Y
M2C&,8IRE)I)-M'ZB_P#!NW_RAU_9`_[K_P#^M0_&NOR)_P""RW@#PG\6?^"]
MG_!.3X5>/M+;7/`?Q/\`@IX0^'/CC0UO]1TLZWX,\<_$KX\>%O%6C'4M(N[#
M5;!-6T'5=0T^2[TV^L[ZW2Y:2UN8)U21?U^_X-Y;2[L?^"/?['T%[:W-G*\'
MQUNXXKN":VEDL[_]ICXRWVGWBQ3(CFVO["YMKZRG`,5W97,%U;O)!-'(WY9_
M\%4/^5B__@E+_P!B7\(__5U?&BO:RNI*GXA\;5:4W&<:7'LZ=2G*SB_8YE*$
MX3CLU=2C*+NG9IIH\K,8)\$<*4ZD4TY\&0G":337M,OC.$XO3O&46NZ:W15_
MX)N?%7XF?\$;?^"@?B3_`())?M-^)-8UO]FOX\^(_P#A+OV)/B5?7&FZGIEC
MJOC;6;^U\,Z=<RI!INHZ)'\3;^TE\$^+?#-E:R:=X<^/>CQZCX;\.OX5^)NL
M_$;4/6?^"UGQO^*_[<?[1_PK_P"")O[(]U=OX@^(%]X3^('[8WCBWT?3[_2?
MAE\,+271O&&B:=K-Y=ZI8R6UAH6EOIGQ7\86!.A7OB2Y?X-^`O"/B34M6\=Z
M[X4N/U&_X*^_\$U/#'_!2G]ES5/`5@N@Z#\?/AW+>^-/V??B!JUA'(='\6B"
MV75_!&K:K%Y>JZ=X&^)^GZ?:Z!XH-G-/:Z9JEGX3\=W6@^)K[P)I.BW7B?\`
MP11_X)B^*?V(OAAXU^-?[3;VWB[]NC]I;7-1\7_&GQCJ6K1^,O$7@[1M3U*;
M6+;X:MXY&IZO::_K&H:U/=>./BGXCT&Y6P\5^-M1L]-GU+QCI7P^\(>*KS%9
M[D-6G#CBM*B^+,-26$J9/[.*I8W/E&,<)Q,XQ:C]7IX=5,3BZ,8P3S2E0490
MC7YI]#RC-H3J<*4U57#M:;Q$,R4FZN&RAROB<A<I*[K3KRC0P]5RDXY;6K/W
MIT%"'XZ_L)_`?X>?LP?\'+7Q-_9]^%&FMI?P_P#A+^RWX,\&^'HYX=,CU/48
MM-_90_9Y^W^(_$$FC:;H^FW_`(K\5:M)J'B?Q=K%KI=@NN>)]8U;6)+6&:^D
M6OZ=_P#@I;_RCF_;Y_[,O_:@_P#5)>-Z_GM^#7_*V5^T_P#]D-T3_P!97_9Z
MK^A+_@I;_P`HYOV^?^S+_P!J#_U27C>CBBK4K\4<!UZTY5:U?AS@>M6JS;E.
MI5JJ-2I4G)ZRG.<I2DWJVVQ9!3A2R/BJE3A&%.GG'$L*<(I1C"$*]>,81BM(
MQC%)12T222T/XN?^"+__``51_:5_8F_92\6?"7X0?\$U/C;^V!X8UGXY>+?'
MMU\3_AUK7CO3]"TO6-7\%_#K0KGP7-;^&?@#\3[`ZEI=KX8LM7GFE\1V]T]O
MK]HKZ3;11Q75[^L>I_\`!Q-^VOH>FW^M:W_P0Z_:=TC1M)L[G4M6U74_&7Q5
ML--TW3K*%[F\O[^_NOV/H[:RLK2VBEN+JZN)(X+>"-Y972-&8?('_!OI_P`%
M7/V!?V'_`-BCQU\(_P!J'X\GX8?$'6?VC_&_C[3?#W_"K?C1XU^T>%-8^'WP
MIT/3]5_M7X=_#KQ;H<7VC5/#6M6QL9]3BU.'[&)KBRBM[FTFN/W/?_@XD_X(
M[JN4_:]+ME1M_P"&?_VHUX+`,<GX(X^526QWQ@<FOIN*\'"?$N<2EX49CG//
MCZLGFE*MQ5"./4G%_6(?5&\+%5%;^"O8I-M+E=CY[(,14ADN5I>(V!RQ0P6'
MBLOK4<@=7!\M."^KSEB)QKN5)KD;JQ51O65V[GY7_P#!JQX+7Q7+^W-^U5J7
MCWX=7_B;XM>-_!VEZI\*_"6MWLOB_P"'\_\`;7Q*\7:EJWC7POJNF+=Z-X;\
M6W/B"TB^&.L6FOZY::W%X;\;6-U<C5?#][!;>]_\'97_`"CM^"O_`&>E\/?_
M`%1O[15?$/\`P;*^)V^)O[>O_!2KXJ?#O1]1\._!+Q@/^$IL?#;B"TM?#S^/
M/C!XV\1_"C2-2TVRFN;&#5-,\'P>-].L5@GN+>TAM]8@L[B6&0M)]O?\'97_
M`"CM^"O_`&>E\/?_`%1O[15<^+IU*7C5EBJ2O*6*R6:I6C&6$IO*<.J6#J**
M2<\-!*GSM<U1152?O29TT90EX6XWDA:,*&94_:7;CB91S.MSXN+;=HXB;E5Y
M4W&$I.$7RQBSXD_95_X.#OVC/@I^R_\`LX?!O0/^"3/QF^(VB?"?X#_"+X:Z
M/\0=*^)/CJRTSQUIG@;P!X>\,V7C+3;&U_9A\06MGI_BBVTR+7+.TM]?UR"V
MMKZ*&'6-3C1;V?\`I%_X)D_MR>/OV_?@7XP^,'Q$_9G\5_LK:SX9^+6M_#:U
M^'OC#Q#JOB34]6TS2/!O@3Q/%XPAO-9^'7PSO+>RU"[\87NC167]A7D23Z!<
MW":O,;EK+3_S&_8:_P""[?\`P2H^#O[%?[(?PD^(W[4W_"._$'X7?LQ?`?X>
M>.M`'P/_`&CM8_L3QCX,^%OA3P[XETC^U=!^$&J:)J?]FZSIM[9?VAH^IZCI
M=[Y'VC3[ZZM)(IW^IO\`B(C_`.".O_1WY_\`$?OVI/\`YR5>#Q)E&)QSQE++
M/"_.LMQ;QU2:S2BN(\=[:FJL^=QP^(H2PZCB4XS4H?`FE3;B]?7R/,J&$6%J
M8_C_`"G'8=82G'ZA/^PL)[.;I4U%.O0JJOS4/A:D[S?QZZ'[5U_GY?L7_MY_
ML]?\$^/^"V__``5)^+7[1^K>)M(\'^+/BE^U[\/-&G\+>&+[Q5?2>)+[]K6R
M\2P13V-@Z2V]I_9GAG4V>[8F-9EAB(S**_NG_9\_:"^$7[4_PA\'?'GX$>+?
M^$Z^$_C^'5[CPCXK_L'Q-X9_M:+0?$.K^%=6;^P_&.B^'O$EA]DU[0M4L-NI
MZ/9O/]E^U6RS64UM<S?QH?\`!*SX%_!+X^_\%Y?^"KWA;X[?!WX6?&KPQI'C
M']L3Q#I/ASXM?#[PE\1M"TOQ!#^V+H&EPZYIVD^,-(UBPL=8BTW5-2T^/4K6
M"*]2QU"^M%G%O=W$<F?`\,/A,LX_IYQA,:Z%#*,-3QV#HR6#QT90S&,)4E+$
M4JBH5J=5)3C5I-QY90<5+:^+)5Z^:<%SRZOAE6JX_&5,)7K1EB,+)3RV4X3:
MHU(.I"<'>#A4BGS1ES<MS]A3_P`'.'_!*U4ROC7XQR$`85?@YXA!;V!>=%'_
M``)A7Y&_\$4/C#I7[6O_``7J_;._:@^'&@>([+X:>-OA3\7?$^G3^(;."TU'
M3M&U?Q]\)-&\-)KB6-Q?Z?8:SK,6GR7D>D0ZC>R1)#J"PW%]%IEW=C[S_P""
MQ_\`P0H^&_Q+^'VC_M(?L"?!;X6?"S]H'X%VD.MR?!SP%\+?`FF?#+XY>%_#
MU]+X@_L*\^$]OX;F\!^(/B)8W;3SZ0FJ>&-0LOB/I3W7PZ\;6/B"QF\(_P#"
M-_0'_!"3_@I#^RM^U!\)KKX&>$/A!\'_`-D_]ISP5]JUCXK?`7X7^!?#OPM\
M)>.-0M1!I6K?%?X?^'M#TO28+ZVO!9V5OXJT6[6\\4^";Z.'2=5GU'15T#Q!
MJWJTWP[@N#\[S7A'+LUQ=3,L!4R7.Z>.S'#UJV0TJU>E6AB:V%H8*E*OAJ_L
M(NCBZ=3V*FG3K>RE&<'Q3_MG%<1Y9E_$>-P&%IX+&1S+*IX7`UH4\XG3I2I.
MC2Q%7%5(TJ]'VLW5PU2"J\O+.G[6,XM>Q_\`!Q%_RAX_:^_W?@#_`.M2?!"E
M_P"#=S_E#K^R!]?V@?\`UJ3XVTG_``<1?\H>/VOO]WX`_P#K4GP0K\O/^",W
M_!9W_@FW^R=_P39_9P^`'Q__`&BG\"?%KP%_PN`^+/"J?"'X[>*ETK_A*OCU
M\4?&NA#^W?!OPQ\0>'+[[;X:\2:-J/\`Q+M7N_LWVLVEW]GO[>ZM8/*P&69E
MFOA;*AEF7XW,:\/$"I5G1P.%KXNK"DN',/3=2<*$*DHP4ZD(.;2CS3BKW:.S
M%8_`Y?X@NMC\;A,#2J<'0I0JXS$T<-3G5EG4IJG&=:<(RFX4YR44V^6,G:R/
MZ[Z*_$__`(B)_P#@CQ_T=Q-_XC_^T]_\YBOT;^%?[7W[._QJ_9JB_:_^''Q)
MT[5_V<I?#7CWQB?B?J^E>)/!6CVGACX8:MXET3QYKNJ:?XYT3PWXBT;3/#>H
M>#_$BWMUJ^BV2/:Z7+J-K]HTZ:VNYOAL;P_GN6PI5,QR7-L!3KUHX>C/&9?B
M\-"K7FG*%&G*M1@IU913DJ<6YN,92M:,FOKL+G.48Z<Z>"S7+L9.G3=6I#"8
MW#8B5.E%I.I.-&K-P@G**YY)1YI15[R2?XB_\'&7[9GBSP/\$?AY_P`$_?V?
MVN-:_:6_;L\1Z;\.X_#WA_5+"+Q':_";5=<T_P`.7^DE8O%&DZGH=Y\;/%^H
MZ5\+=!EUS1-2\'>+_""?&;29K[3]3T.*6+7_`&N/^"*/A34?^"+WA?\`8M^%
MNEV6O?'#]FKPO%\7/AWXBT^U=+SXB_'RQAU36_BA;P->7EM>+:?&9M=\8^&_
M#.C:OK*:/X9N]2\`-?R2:;X#TV.#\7OV>/V5/VG?^"_7[7_[3W_!0WPK^TIX
MY_9`\&_"_P"(NB?#S]G#QKI?AWQ!K_BCP_H>D:3?/HG@3PL=$^,?ABZ\!>)/
M"G@;4?#OC'XFW?AKQ$^@:M\0?BOKFK>'K2*#6]2%M^I?_#BG_@I1_P!)_?VQ
M/_,[?_1@U^K3H97PQAN'LF_UOR_(\WR7&PSS.\/7P&;8F=;.ZT*,J5"K5P>#
MJ4)8?`X":P7LZ=>:DZ^,E-1E4LOSR-7,,]KYSF+X;QF;Y9FF'EE>4UX8W+,-
M&GE-.<HSK4Z6+Q,*JJXO&7Q2JSI1O&EAG!RC",I?7W_!`#_@H,_[<W[$6@Z#
MXXUN?5OCY^S6FA?"CXJW6HW=_J&L^+-%73[D_"[XI:EJ&JZMKFKZM?>./#.D
MW6G>*-?UF_2_\0?$CPAX\U<6-CI][IT)_17_`(*!?\F(?MJ?]FG?M%?^J@\8
M5_&%9_#?XL?\&XW_``5%^`?C[XG_`!HU/XY?L_\`[4WAS7M#^,GQ<U#PS>^'
M)_$&AZUXMT^'XHZEJVB2ZM\8/%FI^+/@MK^J_#KXR7NIZ5)+XB\>:=JDO@K2
M]1M9?$_B,)_9M^WS<07?[!'[9MU:RQSV\_[)7[0\L$T+!XI8G^#_`(P9)(G4
ME7C=2&1U)5E(*D@@U\QQ=E&!P/$N69MDLZ=;A[B+$4<RRJO0C4CAX3^MQIX[
M!056%.I!X7%*3A2J4X3AAZM"#7/&=OH.'<RQ>+R3&9?FD)T<XR6F\#F%*K*,
MZLH^PYL'BIRA*<)?6<.ES3C4G&=6G5E&3BXG\4O_``2Z_P""0GPV_P""G?\`
MP2<^+VJ:1<Z+\._VJ_AC^UK\3;3X-?%JZM)5TW5+)_@U^SWJA^%WQ6;3K>?4
MM7^'.I:A<:A=Z1J=O::EXA^%_B/5;[Q=X2L=4L=2\<>!?B#^NG_!'_\`X+!_
M$_PY\4)/^"7/_!4B/6OAS^UE\.]:M?AS\,/B;\1KJW74/B;?^3"WAKX7?$W7
MX[B[TO5OB?K&DW.E7OPC^+%GJFI>'OVC_#VJ:"HUS5?B7JWAOQ%\<>E_X--?
M^4=WQK_[/1^(/_JCOV=Z^Y_^"P/_``1]^%O_``4[^%T6K:5+H7PZ_:N^'FBW
M=I\(OB_=VEPNFZUIPEN+_P#X5+\6_P"RX;C4M8^&6KW]U?7.F:G;6>I>(_A;
MXBU.^\6^$+34].U;Q_X"^(_T?$>>Y?B^)^(>%^*7.632S;$/*\TA'GQG#F*J
MNE>K1N^>O@*TO][P5^62_>4TJL8M_/Y!E>-P_#^2Y_D"@LR6748X_+YR<,+G
M>'IW4:52VE+&THZ87%;W2I5FZ;O#\1O^"TW_`"L0_P#!*'_KK^PY_P"MN_$B
MO[5:_P`QG0?BY^UY\0?^"L__``39^&W[<^GZ_:_M&?LM?M%_LE_LY:]?^,K=
M?^$[U[PCX<_:3TGQSX*UCQSX@AU/5=/^(6NSZ;\0IX=+^*NDW-Q8?$_P/!X/
M\;3ZQXQUK6=8\>^*O].:O&\1<OJ95@>"LOJ5J&(EALBKP6(PU15</7IO,*TZ
M5>A46DZ5:E*%6G+1\LU=)GK<$XR&88WBS&4Z=:C'$9OAYNCB(.G7H5%EV'C5
MH5H/X:E&K&=*5KQ;AS1;BTW_`!B>$_\`E;R\7?\`8L6O_KN_PI7]G=?PG_&7
M]I7X*?LB_P#!TG\4?CS^T)XS/@#X5>$M"\+V7B#Q0/#GBOQ6;"X\3?L%>!?#
M>BQC0_!6A^(_$5U]LUK5+"RW6>D7$=L+@W-V]O:Q2S)_0!_Q$3_\$><@#]KE
M\9`8M\`?VH!@%@"1M^"C[L`EB#M^53@EB%/3QOP_GV9RX2Q66Y+FV889<"\-
M4GB,%EV+Q5%58X:3E3=2A1J0]I%3BY0OS)2BVDI*^'"N<Y/@(\04<=FN6X.L
M^*L]FJ.*QV%P];DEBDHS]E5JPGR2::C+EY6TTF[.WD'_``<P_`SX;?$?_@F%
M\2/BQXHT&"Y^('[.WBOX:>,/A=XFAALDU71KKQ_\5OAY\)O&&BR:C)9S:D?"
M_B'PUXPDO=7T"SO;*PU/Q)X:\%ZUJ,=U<^&=,$7J/_!)C3IOVRO^".W[$VH?
M$75+SPQXV\%>%M3T#X8_$OX>K9Z3XW^%NK_L_P#Q!^(7P.^&GCOP9?ZU:>(=
M.7Q5#\/?"5MH/C*SU_2]=\%?$SP_K_CCP%\1O"/BKX8^._%_@?6OP<_X*U?\
M%@(?^"K=EX6_X)K_`/!-KX<?%;XH3?%7XFZ';^)/%$N@:3H$/QBT_P`(W:^)
M]%T+P?X>\1H?$?A_P%IVO:7I/Q+\7_$3Q_)\*)/!NE>`);WQ59V/@H>(]4MO
MZY?V"/V8-._8Q_8[_9\_9EL18O=_"KX>Z?IOBN]TJ^U/4=(UCXC:Y=WOBSXH
M^(=&N-86+45T7Q)\1]?\5:_H]I/;60T_3=2M=/AT_3H+6*QM^?.</C.'^`LC
MRO-E+"9Y/B7%9UE^"K-+&X#*98"&&E[6B[U,+#$XU2K*A5455;E-P<XU%'IR
MRKA\YXNS7,,N<<3D\<AH97C,52_W7%YDL;*M'V556CB)4,(_9RJTY/V:E%*5
MG!O-^!7[$O@/X'_%/Q#\93X[^(WQ*\>ZSH4WAK3-0\;_`/"OM'TSPCHVI^&/
M@]X0\50Z!X>^%?@#X;Z'=7GC30_V?/@E#X@U/Q38^)+^TE^'6F#PC/X6LM6\
M36.M_9U%%?FN)Q5?%U/:XBK*K44(4TY62C"FN6$(1BE"$4M;1BKR<IRO*4F_
MN*-&E0AR48*$7)R=KMRD[)RE*3<I.R2O)MV26R05^0/[7'ASQ?\``CQ__P`+
M*\&^*=5T6'QMKU[?Z'J.EOXBM;O3-5,ND^*M?\):QKM]JFI6NN67B36],U#Q
M-;>%6EL=!OO#6GS>'/\`A$+G0O!EU=77Z_5RWC7P5X7^(OA;6?!?C/1K/7_#
M6OV@L]4TR]$H26-9X;J">VN+>6"]T[4K"\MK;4-(UC3;FSU;1M5M+/5=*O;/
M4;.VN8L#4_!.P_X*X_%[X7Q26?Q!\`^%_BM96FG306U[9:A)\/?%5UJ8NWEB
MOM5U.STOQ#X7FMDM&6S^Q:;X)TER4CNVNY7$L,_M_A3_`(+F_LL:S-IUAXD\
M!?&OPGJ$Y@AU.Z.A>$==\-Z7<%$^U.NH:?XSC\07^GP2F417$/A*.^N(424Z
M7!+(;>+Y-_;;_P"";'Q;\"V]YXH^#EEK7Q?\$+;QR7%C8VD5W\2-(N)KZ"P%
MO/X;TFW1_%5N_P!JL[K^U/"^GK/$/[8GU+PYHFD:3%J-[_/U;_\`(1GR"#Y\
MN0P*D<MU#`$'ZB@#^U2T_P""J7["%VJ%/C?,C,N2C_"_XPL4;GY28O`$B<*I
M9FWX"X(S\VWV?X*?MG?LV_M$^*;WP7\'?B'<>+_$FG:%<^)KVP;P-\1?#D<&
MB6=YI>GW-Z=1\5^$M#TQS%>ZUIEN;6.\>\+W/RV[+#<-%_$?HO5/\_Q"OVU_
MX(Q_\G*^/?\`LA7B;_U8/PPH`_I=HHHH`***^(/VL_\`@H!^SU^R-X=U6Y\9
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MI.N:'JUO=Z;JNFW<1:*ZL;ZVGMIXR4EC920?CW_@GIKWQ-^)'P`_X:#^+3ZI
M8>*OVG/&.L_&ZP\%7.K1ZMH/PY\`:KIVB>#OA3X7\$O!-);VWAK4_A?X+\(>
M/;I%AL+K4?&'C3Q7X@U73;#6=:U&TA^XIW,<1<=5:/TY!D4$<@]02,XR,\8.
M#3Q5">`Q=7#^U3K82M[*52C/W8XBDU&I[*I%^]&G64HPJQ=JBBJD;*22F$HU
MZ,9R@N2K#FY)I2O":NE.+5KN+7-%J\7>+U1^8NL_\$6O^"5^O:K?ZQ>_L0?`
M^&\U*YEN[F+2-%U+0-,269MS)8Z)H.K:;HNEVRGB*RTRPM+.!<)#!&@"U4M/
M^")W_!*JRNK>[@_8D^#9FMIHYXA/:>(;N`O$X=5GM;KQ!-:W4+%=LMM<PS6\
M\9:*>*2)V0^&?"O_`(*A?M4_$K]AZS_X*(Q_L6?!M?V=;7P;XM^)_BGPYH/[
M9/B74?CMI7PR^''B;7=%^).NZ1X,\1_LC>#_`(<:_P"(/#6B^%?$GBO2_"L_
MQCT%?$]EI\&E6FN6>MW]MI[_`+%?#CQ]X;^*OP]\"_$_P=<SWGA+XB^#_#7C
MKPO=W5G=Z==77AWQ;HUGKVBW%SI]_#;WUA<3:=?V\D]C>V\%Y:2LUO=0Q3QO
M&OT..QW&.67^MYUFU/V>*K8&;HY[5Q"I8O#)>VP]1X;&U/958)_#4Y>=*7)S
M*,FO%PF&X=QR3PV6X"7-1I8B/M,IA0<Z%=7I58>WPM-SA-1^*',EHI6;2=;X
M:?"OX9_!CPAIOP^^$/P]\$_"WP%HSWTFC^"?AWX6T3P9X2TJ74]0NM6U273O
M#OAVRT_2+*;4]5OKW5-1EMK2*2^U*\NKZ[::ZN)I7Y/XW_LY?`3]I;PU:^#_
M`-H'X-_#3XS>&M/N+J]TO2?B3X,T'Q?!HFI7EC/ID^K^'WUJRNY_#^M&PN;B
MUCUK19;'58(I6%O>1'FJFO?&.71/VDOA3\`/[`%S'\3?@S\?OBY_PE/]J>2=
M%_X4=XR_9L\(?\(^=$_LV;^TO^$G/[0O]HC51J^G_P!B#PC]C.F:O_;_`-JT
M7#^+_P`?G^%?QI_9-^$@\*_VXG[3OQ(^)'P]?7?[<&F?\(6?`/P%^)WQN36/
M[,_L;43XC_M/_A6Y\,_V>-1T#[%_;0UDWUY_9O\`9-_XE*&9>WHXJC4Q$<5B
M*.)S"CBH8IPQ,J=!8EXG$*NJL:L)Q6&Q-[SC5GR-04N>'-Z-2I@'1JX>K&C+
M#TJN&P-6A*AS454Q/U98>@Z7LW"4)_6<.M(NE%3]]Q49\OQY_P`.1/\`@E+_
M`-&2?"#_`+X\4?\`S25M^'O^",?_``2S\,:M::UIO[#WP'N+RR<R01:_X:N/
M%6E,Q1XR+O0O%&H:QH=_'M=OW5]IUQ&&VN%#JK#].*^&OVX?VQ]3_94\,>`=
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M_M'?$3X/>$O%GQP^$<&GVOPX^)&IQ7YU_P`)P:3JFI:WID>FF"^ALB+'5M8U
M.^@^U6EP5GO)2#MVJ.U_9_\`CG\//VF?@I\,OC[\*-7CUOX>_%CP?H_C/PS>
M">QENX+35;</<:/K,6GWE_;Z=XE\/7ZW>@>*=$:[EN]`\1Z9JFB:@(K_`$^Y
MAC]:N&9(7*-M;Y55L`[2S*H;#`@XSG!'.,<=:\=5,7@L164:F(PN)C]8PN(Y
M:E2E67-ST<50JM.,VI^_3K4YMJ7O1FF>@XX;$4:<G&C7H-4ZU)\L*E)J/+4H
MU::LX>[:,Z4XJ\6HR@T[,FHK\9/#'_!1O]K?6/V,M&_;\O\`]C+X(S?L^/\`
M"JV^._B;0?"7[9?BO5?CCH_PBLX!K/C76-*\&>+?V0/`?P[U_P`6>#_"%MK/
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MGA_PYH>E`Q6$<GV;3H,N9#)(_M/COP-X3^)W@GQA\./'FAV?B;P/X_\`"^O^
M"_&/AO41*=/\0>%O%&E76B>(-$OA#)#,;/5-*O;JRN1%+'(89W$<B/AQ\"_M
MO_\`!0NT_8C^+'[-_A?Q3\+;OQ;\*_BY#X^USXP?%>U\;:3X=C_9Y\`^"_'/
MP#^&0^(^K^%M3T:XD\;^%8/&/[0WA&7QFVF>(=$U/P;X2T_6_%D=AXBM-/N[
M2U]\_;'_`&H-,_9,^#$_Q%'A>3XB^//$OB[P9\*/@I\(K'Q/X=\(Z]\9/C=\
M3O$%GX5^&_PUT+6?$\\.G6+ZQK-]_:/B35Q!J<_A3P)H_BWQJVC:M:>&;JRE
MZ)8+.<1_8U>?UBM_:$?J^3U98I3]W`UWA50ISE5MA%A*J5J=1T51I2IUTHT:
MD)O!8G*Z:S*C'V,%A&JN8TE0E%)XFC&LJDX>S2Q#Q%/>=-5?;5(SI-RK0J07
MRK_PY$_X)2_]&2?"#_OCQ1_\TE2P_P#!$K_@E1;RQSQ_L2?!TO$ZR();?Q)-
M&61@P$D,WB%X94)&&CE1XW7*NC*2#]F_LH_')OVFOV9_@-^T._AD>"V^-GPH
M\#?$\^$1K/\`PD0\-?\`":^'K#7QH?\`;W]DZ%_;/]F"^%G_`&G_`&+I7VWR
MOM']GVGF>0GNFI:C8:/I][JNJWMKIVF:;:7%_J&H7T\=K9V-C:0O<7=Y=W,I
M6*WMK:".2:>>5ECAA1Y)&5%8CIKY[Q3A<15PU;/,[AB*%6="K".;8V;C5IR<
M)P4J>)E&34DXWA*2E]EM,BEE>1UJ5.M3RO+)4JM.G5IR_L_#1YJ=2,9PE:5%
M2C>+B[22DMFD[H\X^$7P,^"WP`\-WG@[X%?"/X9_!CPCJ&L7'B*_\+?"GP)X
M7^'OAV^\0W=G8:==Z]>:+X3TO2=-N=9NM/TK2["YU2>V>^GL=,TZTEN'M[&U
MCAY3]HW]EG]GW]KGP3I7PX_:1^%OAOXN>!]$\4V?C72O#GBA;]K"Q\5:?I.M
M:%9:W!_9][8SK>V^D>(]<T^-FF:/[/J=TK1L7!7Y3_8E_P""BFE?M<^.?&/@
M;5_A7XC^#]SJ'A*/X[?LV7WBO51,_P"TG^R7J_CKQ/\`#_PI\??#_AZ_\/>%
MO%/@IM3U/PYIVM:UX&\2Z-/=:#X3^)'PC\00>(=;MO'4*V'Z5UPXN&:Y5F4I
M8FIB<+FE*<:SKQQ+>)C4G%352.*HU9-U/>M.4:KG"HITZCC4A.*Z,-+`8[!J
M.'A1K8&<725%T%&BX1=O9_5ZD(I4[6<(NFH2@XRA>$HM_E9_PY$_X)2_]&2_
M"#_OWXH_^:2C_AR)_P`$I?\`HR7X0?\`?'BC_P":2O<OC7^UOXL\.?'/1?V6
M/V=?@O/\>?C_`'7@:U^*WC5=>\9R_"?X'_!;X9:AK=]X?\.Z[\7_`(O+X,^(
M6HZ?X@^(6L:+XDTWX<_#WX?_``\^(OCC74\,^(/$&LZ1X6\'::WB=]GX:_$O
M]M1/B9X6\'_'/]EOX3:5\/\`Q3I7BR>[^+WP&_::NOB?8_#[7=!M]-O=!TKX
M@^`_BI\$OV?/%#:/XTBN-5TO1/$/PTD^)E_8Z]IUG%XI\*^'/#^I2^)--]?^
MT>+(T%B*F?YE1C*B\1"G7X@G0Q%2@DY1J0P]7&PK-58IRH1Y.?$QM+#QJJ4'
M+@^J9`ZKI1RG!SE&I[*<Z>31G2A5O%.$JT,(Z2Y'959<SA1<6JTJ;1[S\&O@
MQ\+_`-GOX;>&?@_\&/!FD?#WX9^#8M1@\+^#M"6X72=%BU?6=2\0ZDEHMW<7
M5P%O-:U?4=0E\R>0^?=RE2J%47RGX5_L3_LK_!+XR?$?]H3X4_!7PAX)^,_Q
M=F\2W'Q*^(6CKJ8USQ?-XP\30^,O$TFJ&YU&XL]VL^*+>#6KS[-:09O(U,?E
MQDQGZEK\JO@Y^VO^UO\`M(^+/VG=,^!7[+G[.UYX2_9H_:E^*7[+&I>(?BW^
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M>_%SPKX*\%?$&5M3&O\`AKX>>/M;^)_@_31%K&H0Z.='\<>(_AO\(]9UO[;H
M,>EZC?\`VWX>^'CINIWE[I$`U6UL(-;U+R+]H?\`:#D^!7B3]F'0$\*?\),O
M[1G[1^E?L_O=?VX-%;P>-4^$WQ>^*(\6K"=%U@:^;?\`X52=".A&31O-&O\`
M]I_VS$=+%AJ.6#EF-&O6H8#$5J5:I1KTZ_U3%^SA7H4J<JV(A*K2JQIUZ')2
ME/E<I0JJ*Y%)RBGIBOJ;HTZ^,I4YTZ52C4INOA_:2I59RC"C.$)TY5*57FJ1
MBI*,9PYG=Q7-;T#XV_`[X3_M'_#/Q'\&_C?X(T?XC?##Q?\`V.?$O@S7OM9T
MG6#X?U_2O%.BFZ%C=6=R3IWB#0])U6W\NX3%S90[MT>]&^`_^'(G_!*7_HR3
MX0?]\>*/_FCKZV_:E_:'E_9P\-_"7Q%%X4'B[_A9W[2?[/'[/;V9UP:"-&7X
M]_%7PU\,_P#A+OM!T76SJ!\*#7SK0T$0V`US[+_9QUC2//%_!].UMAL?G>6X
M2G/!YAF&!P>)K5^2.$Q]>A3JUZ,:$:\G2H5HVG&,Z,7.<%SKE49247RQ6PN6
M8W$2CB,'@\5B*%.GS/$82E6G"G4E.5-*I5I2O%RC-J,9/E=VTN;7\K/^'(G_
M``2E_P"C)?A!_P!\>*/_`)I*^O-._8[_`&:='_9RD_9&TCX2^'M*_9OET_5=
M)E^$NFW.M6/AN32]>\5WGC?7--D>UU6+59-/UKQ-J%_J.KV3ZB;;4UOKVPOH
MI],N[BSD^<OVI?VH_P!LG]FO0M;\?Q?LR_LT^-_AA#\3_A;\-_#.J3_MA?$_
MPQX]U9_C/\8O!/P7\#:MKO@N+]B3Q#X>\/B#Q#X_T34?%-EI_P`0/$W]D:+:
MZK+I=YXBOX+2QO\`ZQ^#&N_M):VWB9OV@_A=\%/AJEO_`&-_PAZ_![X]>./C
M>-9,HU/_`(2`^(/^$S_9N_9\;PP-/\K1?[)%@?&#:TU]JINSH":59C6>O%XC
MB*K@\-CL9F]?$X:->-7"^USZ.*K4\515&:G2PKQ=2O3Q&'6(I.4U3A4HJ;NT
MN8Y<-3R:.)K87"X"A1K^QY:ZAE4J$98>JYQ4:E;ZK"E.C5=":493<*W(^536
M^E\"O@!\&OV9OAWIGPF^`WP\\._##X=:/>:KJ&G>%?#-M-!80WVMZC<ZMJM[
M+)=3W5[=W=Y?74LDEQ>74\JQ""UC9+2UMH(O8:^8OVT/VBV_9'_97^.7[2J>
M$/\`A/F^#/@34?&__"&?V^/"W_"1C39K9#I?_"1'0_$HT?[0)B/MO]@ZKY6.
M+1R<CZ=KQZT<55A_:&(E4JK%XG$TWB:U7VM6MB:,</6Q/M)3G*K*:CBZ$Y5*
MBM-U'RRE*-11]*DZ%.7U2BH4W0HTI*C3I\D*=&HZM.BH*,534;T*D5"'PJ&L
M4G&_SQ^T?^R=^SG^UYX4T3P/^TG\)/"GQ>\*>&_$">*M#T?Q5!=O%I>OIIU]
MI(U&SN-/N[&\BD;3M2O;66(7'V:=94>:&22WMGB[6V^"GPMM/@S%^SU;^#-(
M3X+0?#8?!^'X=LMS)H,7PS7PW_PA\?@U$>X:Z72(O#&-%BC%SYT5DJI',K*K
M#Q#]I;]JR?X+>+/A1\&?AM\+O$GQS_:+^.L_B:7X=?#30]0B\*^&=#\)>!;?
M2+GQ]\6_C-\3]1TO6-&^%OPC\%OXA\-:3J>NKHWBWQEK_B3Q3X=\-?#WX?>-
MM;O;FSL>8T3XH_M_:/XU\"VOQ(_9&^!6K?#SQ3XOLO#?BS7O@-^UUJWC/QE\
M,=&U&PU9D\?ZOX.^,O[-_P"S]HOC#PAHFJ6VD6WBN'PIX_\`^$]MM/U674O"
M?P_\9W6GMHESW1H9I4P6%;Q*IX*+JXO`T<3F5##1;4I0JXG!X:OB:;M.=.=-
M5Z5-*O6I3I4I5*U*4(\TJV!CB*]J7-7:IX?%5:.$JU7KR.G1Q%>C1G%\L9PF
MX5)OV5&<:DU"E44G[3^SE^RS^S[^R-X(U3X<?LW?"SPU\(_`^M>*;WQKJOAS
MPLE\MC?>*M1TG1-"O=;G.H7M_<->7&D>&]#L'(F$8@TVW58U(8M[_0*^*/VU
M_P!KC5OV7O"WP_TCX8_"B7]HK]I#XV^,W\$?`C]G72OB!X<^'.N?$:^T+1K[
MQK\0]:E\4>([+5[/PYX3^'GP[T/7?$GB'Q+=:+?:7;:D?#'AJ^N-+NO%VF7\
M?)3AC<UQJBISQ>-Q4Y2E5Q-=<TVHN=2MB,5B9J$*=.G&52M7KU(TZ5*$JE6<
M81E);SEA<OPSERPP^&H12C"C2?+!.2C"G2H48.4I2G)0ITJ4)3G.484X.32?
M=_%;]C+]EKXX_%CX8?';XK_`WP!XU^,GP9O]&U+X9_$O4]):+QEX6N?#?B&'
MQ;X;2WUNPGL[R_LO#OB>%]>T'3=7DU#3M&U2]U:\TRUM9M:U=[[Z<KQ?]G7X
M]?#S]J'X'?"_]H'X4ZE_:?@+XK^$-*\7:$TESI=QJ6E->QF+5O"WB)-&U'5M
M.T[QAX-UR#4_"7C70X=2O)/#WBW1-9T*ZF:[TZ<+[),Q6-W!(*`/QC)"D,5^
M96`W@%2=I(!R.0*C$SQ:<<'BYXB^!E4PL,/7G4?U5JK+VM&%.;:I?OG-SC%1
M3FW)ZMLJC'#\KKX>%)1Q*A6E5I0BO;IP7)4E**7M'[/E492NU!1BO=22^`/C
M/_P2M_X)\?M#_$OQ+\8OC7^RS\-_B)\3O&+:2WB;QEKRZ^=6UEM"T+2_#&D&
M[-GKEK;$V.@:+I6EP^5!'_HUC"'WR;G;SS3O^"*?_!*W2[ZUU&U_8B^"KW%G
M/'<0I?:;K>J6;/&=P6ZTW4]<N].OH&^[+:WUK<6LZ$QS0NC,I^KOV-OVAV_:
MS_9:^!G[2;>$?^$";XS_``_T?QT?!O\`;X\4_P#".?VL)6_LO_A(1HGAL:Q]
MG$>/MO\`86E^;G/V2/'/TQ7JU<WXDRVK4RZ><9OAIX"<L'+#4\TQ7L\/+"OV
M+HP5'$.CR4G3Y(^S;IVBN1N-F<-/+LFQE.GBXY=E]:.*A#$QK3P-#GJQKQC5
MC4DZE%5.:I%QE+VEIW;YU>Z/$/@[^S-^SG^SQ_;8^`7P$^#/P0'B?^S_`/A)
MA\(?AAX)^&J^)#I(NUTEO$*^#=$T8:V^EKJ&H#37U3[6U@+^^^R&'[9<^;[?
M7YTZI^U1^TE\1?C[\>?@M^S%\"/@CXKTS]FC6OAQX4^)7C+XY_M,:O\`"F]U
MKQG\0OAQH?Q7CT?P/X$^'7P&^//B,>&-)\'^+O",<WQ!\;-X2L]8\37?B30?
M"GAWQ%#X1U;5U^W?AEK?CCQ)\//!6O\`Q,\#V?PS^(6M>%]$U3QI\/-/\66O
MCNS\$^)+^P@N=7\+0>-+'3-&L?%*Z'>R3:<VNV.EV5EJ3V[75I"+>2,GBQV&
MQM/EQ..JQJ5L1"A6E[3&4*^+<,30C7P\ZM-5ZF)2GAY0G>I!<BE"$^64HQ?1
MA,1A)\U#"0E&E0=2FG##U*6&O1JNC5C2J>SC2DX5E*,E%MR:E./-%2D=S111
M7G':%%%%`!7RY\;OV+/V7OVB+J75?BM\'/"FN^)9I8)YO&>GQ7OA;QM=2VFG
M?V38_P!I>+O"EYHGB#6[;3[`1P6.F:YJ&I:3;BWM<6#+;1*OU'10!^(?C#_@
MA]\'9TMV^&?QH^(_A*X$TTEY_P`)MH_AOX@V;Q/('A@T^WT6+X;75F(!NB\R
M\U#57ECV%L2J\DORE^T+)<?\$%/!_AO]K-47]JI?BIXQM/V:)?`1<?`UM!;Q
M=HFN_%)/&?\`PD^SXQC5!8?\*<?13X=7P_I_VLZ^-1_MZU&E_8=1_IIK^9O_
M`(.I/^3"?@)_V>U\/?\`U1'[1]?2\'9?A,UXGR7+L?2]O@\9C84<11]I5I>T
MIRC)N/M*,Z=6.J6L)QEYGC<0XO$8')<PQ>%J>RQ%"BITJG)"?++VD(WY*D9P
MEHVK2BUY7.?\"_\`!Q'X@^)MI''H?[*FF^%K^\5?)N]3^,LWB>U@D)4[FLK;
MX6^%Y9X\%E,?VVW?JPF'RY^[/@)^W3\?_B^;NS\3CX;:+%J96'2[WP5X0UK3
MM7T:.4*%E:?Q3XS\::1J5Y&=S+)-H4%H2WSV#!<'^,?]F#_F%?\`;.OZ<?V,
MYP]Y;0VEMJ6K7UE:6FJW&D:!I.J>(]?72Y=0MM+&J1^'M!M-1URXTR._NH(+
MK4+?3Y;2SWF6[FAACDD7]/XPX5X?R>A6>7971H2BFXN4J^)DFF]8_6:E9W=N
MG338Y,FQN*Q=*$\16=24HW;Y803=H6TIQBEJ^B2UU/JO]IKQS\3K"RM].N?B
MM\0]1DT6TUFR>_BUY/";:]#JT#6UV/%&B_#RS\&^$M?"VL@M[2*_\.20603[
M3:Q17TMQ=R_FA^RE^PQ/^U[\:X+'6]`N+7]GCX;7]F/BAJ%G-=^'-.OQ#807
MNB_"GPS?:4;.\.MZY9R:?+K4?AR[TZY\$>"+E=8N=5T'5M<^'UOXC_=?4/V2
M]5^,?B(ZG\1WE\(>#;?5(K@:#87UG>^*?%$>E>(]4CN+'5+JR>\TKPYX9\1:
M;I.BW<-SI&IWWBZ\\/\`B;4+,GX;>+=(M[Y/NGPEX0\+^`O#VG>$_!F@Z7X:
M\-Z2MP-/T;1[2*RL;=KV[N-1OIQ#"JA[K4-1N[O4=1O)3)=:AJ-W=7][-/=W
M,\TGP6'XI>497/"Y;RK'8BFX3Q$%RPPJDG%RI\J2E646W3</<IRES-N4>5^M
M/"*M4O57[M--Q>\I1Y;*W\FCYKV;M9*SN;EM;6]G;PVEI!%;6UO&D-O;P(L<
M,$,8"QQ0QH`D<4:@)'&BJB(`JJ%``9>G%M(3G@Q]`6/^M3H%!)/L`35JBOB/
MQUOK?UULT_Q.[RZ'\_G_``2Q_P""4WP3L?V#/V:M*_;$_9RU+6_B_H-EXTO/
M&GPO^-7C'X@>-_`>F:P_Q*\=-H<UY\$/$7C;7?@O#<?\(Y=:9>VAMO!.U9+D
M:GQJ<\URW]`=%%>CF>:8S-L77Q6+K5)NMB<3B8495:M2CAGBJKJSI8>%6<_9
M4D^6$8I_!"";?*CCP.`PV7X>EA\/3C%4Z-&BZBA"-2JJ%-4X2JRA&//.UVW:
MR<I-)79^<O[3?[*_A+]I;]K_`/9GNOBI\.]3\:?"3P+^SQ^U_::IJ-OK?B;P
MYINB_$/QC\0_V)KCP'87>J^%-<T'4GO-<\->#?B;<6-D]S/82PZ'J$US$MS;
MV#'QOQ9^P#\+_@[^V%_P3Z^*/[._P>UC2+'P=\8OC?=?%GQ);^+O'?B>Q\/>
M$-;_`&1/CUX3T*\U:#Q?XLURULH+[QSXA\-Z);7=E:I=M?ZI;6[2"WFEK]?J
M*WHY[F%"C0P].M4CAJ&7X[+OJ\:U:-"I2QZQJJU*E)5.252/UZ?*[*+]G3YH
MNSOSU<GP56K6K2IQ]M6QN#QKK>SI^VA+`O!NE2C4<'/V;6"A&:;ORU*JBUS:
M%?BUX0^!/[=/QU_:P^+O[:-C\1/A_P#LW0>'XO$G[+W[-?P]^.GP`\=_&N^B
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MO`T?BWQ%\7;#28K>[O\`3=$M?U@O&"P.3P!M;H3]V1">`"3P#T!^AJU148_'
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M2KODA%^TJ17[R*:I<RYX4XU)UIU?SY_:$^!TOQC_`&Q?V?\`_A*?`LGB_P""
M%S^R3^W;\(/BV]Y;M+X;D@^,_B']D&VTSP;KC)-!*1XV\-^#?'L,4=NVXVFC
M:EF>WD$#2?(?[&G[+?[4T?QU\)V?[6-W<ZS\(/\`@F_X7\3_``<_8_\`$L_B
M'4K_`%3]H;6?'\.IZ;HW[2?CS3M,E\.6'_"7_"S]EJ^\'?L_Q6^N>&/%0O?B
M-XJ^/_BW3?%4E[=V_P!G_<*BG2SW&4<$\#3C0]FL)+"4JLH3E7P_M,1C:M:M
MAY^T4:=2O0S#%8&NE!TZN%FE.#K4J-6G$\IP\\5]:E4K.3Q*Q$H)P5.;C0PM
M*E3J1Y'SPH5,'0Q-&[3C6C*[E3J583^+_P#@G-X$\7_"[]@O]CSX;_$#0-0\
M*>.?`G[./PA\)^+_``UJJ)%J6@^(]"\$Z/INL:1?)&\L:W>GWUO/:SA)'021
MML=EP3XM_P`%,_`/[0G[27P^\'?L6_`FVU3P?HG[36J>(?#W[0/[05SH<^N>
M"_A%\!?#&@_V[XN\/ZE8Z3\0_A]XFU7Q/\;]1DT/X4:5X?T6]>'4O!>N?$:3
M4]8\)O;:7K:?IS16,<TK+-:F<.G0EB98C$8R$)0<J-+%593J4:RIRDU/ZK6E
M&M3IU>>E4G3C&O"I2<Z<M98"$\OAEKJU51CAZ.%E.#Y*M2A2C3IS@Y1LX^WI
M0E3J2I\DXQJ2=.4)J,U^%'[3/[(7_!0#PS9?`W]I#X<_%G]FSXI_$C]AO5+C
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M&\^-_P`-?'/[/>E^.=&\#_$?P!X2\6>)/">C^//AMJ_@OQ4="\;>!?#5_J'Q
M2M_$^FZ5XB\&:)XIMM1UG0K?Z"^'_P"V#X@^,/Q&\'^%/A=^RS^TH?`5Y=W/
M_"R_C)\:OAQKG[,_ACX>:<OA'Q9JVGP:5X)^.&G>$?C!\3/$VH^+-)\,>%OL
M7@[X=R^#=.L/$U[XCU+X@6KZ#!H6O?;%%55S"GB*=-XG!TJV*I82E@J>)]KB
M(<U'#T(X;#2K4HU+3K86A3I4\/*G*C2<:-/ZS1Q+YW-4\%.C.?L<55IT*F(J
M8F=#DHSM4K5'6K1IU)PE*-.O6E4J5E+VD^:K/V-2@N51*_E_^#?[-?@+P7\7
MOV]M4_:C_8%_:S^+.N?%#]OK]H#XJ_"WQO\`"[3?$<GA;5_@WXIC\(V_A6YB
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M&4+Q?XO_`!V^)WQ"_;R\0_LJ_"OX(?LZ_M#^"_#_`(#_`&LOV=/VB?CG\4/V
MBO@YXL^`7A+X?^"?@%XR3XJWW@_0K7XGQ^&/%7Q,^(WBOQ-X5\.^#M#_`.%6
M^&O'?@&SCUNYUOQ#XUT?2K:"\G_:"BBGB\9'$4\/AZ-".&PV%]LZ=-3E5G*I
M7E&56I5JSMS2?)"$5"%.G&E3@N1U/:5:AA\,Z-2M6J576KU_9J<^2-.,84HM
M4Z<(1O9)RG-RE*<Y3G+WE!0A#X>_X*'>`O&/Q+_9LC\)^`O#NI>*?$?_``T)
M^QGXI_L?28EFO3X>^'_[97P"\?>,]5$;.@:V\/>#_#6NZ_?[29!8:9<M$DDB
MK&_W#1164\3.>$H8-QC[/#XC%8F,E?G<\73PE.<9:\O+%8.FX62=YSNVN51T
MC0A'$U<2G+GK4:%"2=N51P\\1.+6E[R>(DI7;^&-K:GP!_P50^&WCKXP_P#!
M/#]KCX7_``R\,:GXS\?^-_@]KV@^%/"VC)'+JNN:O=3V1M]/L(I9(8Y+B78V
MQ6E0'!YK[_%%%$L3.6#H8)QC[.ABL7BHS5^=SQE'`T9QEKR\L8X&FX6BG><^
M9M<JB1H1CB:N)YI.56A0H..G+&.'GB:D9+2_-)XF2E=M6A#E2?,Y?F+^TU\%
M/BS\.?VQOA/_`,%"/@5\.;KXY:OX>^!GB_\`99^._P`%=.\2>&_#OCG7O@UX
MF^('A;XE>&_&?P1N?&VO^#O`,GQ#\#>-]&N[GQ#X=\;^+=(T_P`;>"M2NM,T
M+4=,\4Z9I*ZIZ%HO[<6N?$/7?"'A7X/?L@?M:>(]:U?Q#X5LO'>H?%?X2:]^
MS1X'^$OA>_\`%>C:3XR\1^(?&7QPM?"MMX_OO"OABZUWQ'I/AKX$V'Q;N?%U
M_H]EHT5]HVEZP_BK2_OBBNK^T*=2AAZ6*P=+$U,'1EA\/6=7$4FZ+G4J0IXB
M-.HO;*C.K-T94W0J)-0JSJTX4X1YU@I4ZU:IA\3.C#$U8UJ]/V=*I^\4(4W*
MC.<6Z;J1IQ]JIJM%N\J<:<Y2DROQ<\/_``,_;E^/7[8'Q;_;$T[QWX#_`&:=
M/^'\7B7]EK]F7P'\=/@%XU^-;W_P6T[4O#FN>/\`X^Z7H/A7]KGX0:%X/\0_
MM`?$K1S:/-K_`((M?'$GPJ^%OPJLYQIMI/?#6?VCHK/`YA5P"Q3H4Z$JF*H/
M#.I7H4L0J="<DZ\84J\*E%NO&*I3E.G)JE*I"-O:-FF*P=/&>Q56=94Z-55E
M3I59T>>K&+5.4ZE)PJVI.3J1C&<8NHH3DI.G&WY)_L9_";]J?]DS]J#XS_"/
MXF:CI7QA_9^_:0;Q1^U!X2^+'P\\#^*?A]X'^$?[1.N>)Y?^%W_!X_#_`,6?
M&'X]^(?#'AWXJ?VCIWQT\/:HOC+0_`T7Q`O_`(KZ3H6A6EWK]EI]O^LMR<6\
MQ_Z9M[]O8?TJ>BIQ^.JYCB%BJ\*,:[I4(5I4::I0KU*$536(G2@U3A5J0C35
M7V4:<)SBZO(IU)N3PF$A@Z+P].=25%5*DJ4:DG-TH5'SNC&<FYRIPFYNGSRE
M*$)*FI.$(I?A[_P3W^/OQ$_9E_8F_9E^`'Q(_8H_;6/CWX4_"WPWX+\4MH/P
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M[U154X0I4J,9^VG";GB/91C]8K4N14\/5DHRIT)3A+VDYSJ,HHHKR3T`HHHH
M`****`"OPO\`^"\?[,7C?]LGX.?L6?LV?#Z:TLO$7Q-_;Z\"6<NK7S6QM/#O
MAG0OV<OVH/%'C7Q1-;W-_IBZB/#/@_1-;UR+1X;^VO-<N+&'1=/E_M#4+1'_
M`'0JI<6%E=S6-S<VEM<7&FW$EWIT\\$<LMC=2VES82W-G(ZEK:XDL;R\LGFA
M*2-:7=S;EC#/*C>GDV:5LES/"9IAU%XC!SG5H<ZO!5G2G"G.4;/FC"<E.4/M
MJ+C=7NN+,<#3S+!UL%6<E1Q'LXU7%VE[-583FHOHY1BXJ5FXWNDVK'Y;?LK?
M\$<?V)?V8/#VBVQ^'J_&CQK9Z5<Z?K/CCXPRR>*H-:DOYH+F\DC^'<TH^&>E
MPVTD"6FARP>%9_$&G:2OV.]\1ZO=76J:CJ/Z:^%_"OAGP3H6F^%_!WAW0_"G
MAK1K6.QT?P]X;TFQT/0])LH1B*STS2=-@MK"PM(LL8[>U@BA0LQ5`6)._166
M.S/,<SJRK9ACL5C*LI.3E7K3J)-[\L')P@NT8145HDE9&]##T,-"-.A2A2A!
M*,8Q6R226NK>BW;;>[U"BBBN$V"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
0*`"BBB@`HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
